BAYN Relative Valuation - Bayer AG

Watchlist Manager

Watchlist

Price: 39.045 EUR -2.81% Market Closed

Market Cap: €62.9B

Relative Value

The Relative Value of one BAYN stock under the Base Case scenario is 79.87 EUR. Compared to the current market price of 39.045 EUR, Bayer AG is Undervalued by 51%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

What is Relative Valuation?

How is Relative Value calculated?

BAYN Relative Value

Base Case

Undervaluation 51%

Relative Value

Price

Worst Case

Base Case

Best Case

Valuation Multiples

View Details

Multiples Across Competitors

All Multiples

P/S

P/E

EV/EBITDA

EV/EBIT

Forward Multiples

			Market Cap	P/S	P/E	EV/EBITDA	EV/EBIT
DE		Bayer AG XHAM:BAYN	37.8B EUR	0.8	-10.4	6.5	9.1
US		Eli Lilly and Co NYSE:LLY	856.7B USD	13.1	41.5	28	29.9
US		Johnson & Johnson NYSE:JNJ	566.8B USD	6	21.1	14.7	18.1
CH		Roche Holding AG SIX:ROG	243.3B CHF	4	18.9	11.2	12.6
UK		AstraZeneca PLC LSE:AZN	216.4B GBP	4.9	28.3	15.7	22.2
US		Merck & Co Inc NYSE:MRK	282.6B USD	4.3	15.5	9.6	11.7
CH		Novartis AG SIX:NOVN	222.2B CHF	5.1	20.5	12.7	16.3
IE	E	Endo International PLC LSE:0Y5F	237.1B USD	102.3	-81.1	375.3	941.3
DK		Novo Nordisk A/S CSE:NOVO B	1.1T DKK	3.4	10.3	7.7	9
US		Pfizer Inc NYSE:PFE	153.4B USD	2.5	19.7	7.6	10.1
US		Bristol-Myers Squibb Co NYSE:BMY	115.7B USD	2.4	16.4	7	8.6

				Revenue Growth	P/S to Growth
DE		Bayer AG XHAM:BAYN	Average P/S: 13.5 0.8	3%	0.3
US		Eli Lilly and Co NYSE:LLY	13.1	19%	0.7
US		Johnson & Johnson NYSE:JNJ	6	6%	1
CH		Roche Holding AG SIX:ROG	4	4%	1
UK		AstraZeneca PLC LSE:AZN	4.9	7%	0.7
US		Merck & Co Inc NYSE:MRK	4.3	5%	0.9
CH		Novartis AG SIX:NOVN	5.1	5%	1
IE	E	Endo International PLC LSE:0Y5F	102.3	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	3.4	2%	1.7
US		Pfizer Inc NYSE:PFE	2.5	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	2.4	-5%	N/A

				Earnings Growth	PEG
DE		Bayer AG XHAM:BAYN	Average P/E: 21.4 Negative Multiple: -10.4	N/A	N/A
US		Eli Lilly and Co NYSE:LLY	41.5	32%	1.3
US		Johnson & Johnson NYSE:JNJ	21.1	7%	3
CH		Roche Holding AG SIX:ROG	18.9	14%	1.3
UK		AstraZeneca PLC LSE:AZN	28.3	26%	1.1
US		Merck & Co Inc NYSE:MRK	15.5	14%	1.1
CH		Novartis AG SIX:NOVN	20.5	14%	1.5
IE	E	Endo International PLC LSE:0Y5F	Negative Multiple: -81.1	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	10.3	1%	10.3
US		Pfizer Inc NYSE:PFE	19.7	22%	0.9
US		Bristol-Myers Squibb Co NYSE:BMY	16.4	16%	1

				EBITDA Growth	EV/EBITDA to Growth
DE		Bayer AG XHAM:BAYN	Average EV/EBITDA: 45.1 6.5	1%	6.5
US		Eli Lilly and Co NYSE:LLY	28	22%	1.3
US		Johnson & Johnson NYSE:JNJ	14.7	2%	7.4
CH		Roche Holding AG SIX:ROG	11.2	6%	1.9
UK		AstraZeneca PLC LSE:AZN	15.7	13%	1.2
US		Merck & Co Inc NYSE:MRK	9.6	3%	3.2
CH		Novartis AG SIX:NOVN	12.7	5%	2.5
IE	E	Endo International PLC LSE:0Y5F	375.3	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	7.7	1%	7.7
US		Pfizer Inc NYSE:PFE	7.6	-9%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	7	-10%	N/A

				EBIT Growth	EV/EBIT to Growth
DE		Bayer AG XHAM:BAYN	Average EV/EBIT: 99 9.1	3%	3
US		Eli Lilly and Co NYSE:LLY	29.9	22%	1.4
US		Johnson & Johnson NYSE:JNJ	18.1	7%	2.6
CH		Roche Holding AG SIX:ROG	12.6	5%	2.5
UK		AstraZeneca PLC LSE:AZN	22.2	21%	1.1
US		Merck & Co Inc NYSE:MRK	11.7	6%	2
CH		Novartis AG SIX:NOVN	16.3	9%	1.8
IE	E	Endo International PLC LSE:0Y5F	941.3	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	9	3%	3
US		Pfizer Inc NYSE:PFE	10.1	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	8.6	-7%	N/A

Bayer AG
XHAM:BAYN

Relative Value

Valuation Multiples

Multiples Across Competitors

BAYN Competitors Multiples
Bayer AG Competitors

See Also

Company

Help

Tools

Stocks

Bayer AG XHAM:BAYN

Relative Value

Valuation Multiples

Multiples Across Competitors

BAYN Competitors Multiples Bayer AG Competitors

See Also

Company

Help

Tools

Stocks

Bayer AG
XHAM:BAYN

BAYN Competitors Multiples
Bayer AG Competitors